Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ASPCFNASDAQ:ATNFNASDAQ:LIPONASDAQ:PTIX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASPCFAcerus Pharmaceuticals$0.22$0.22$0.22▼$8.16$1.70M0.691,500 shsN/AATNF180 Life Sciences$0.94-8.9%$0.98$0.66▼$17.75$5.37M0.15798,173 shs60,032 shsLIPOLipella Pharmaceuticals$2.90-3.0%$2.50$1.97▼$12.00$7.39M0.26721,555 shs13,464 shsPTIXProtagenic Therapeutics$4.76-11.4%$3.85$2.35▼$23.80$2.80M0.28544,783 shs667,307 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASPCFAcerus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ATNF180 Life Sciences-8.91%-20.16%+9.42%-24.63%-45.86%LIPOLipella Pharmaceuticals-1.36%+33.03%+20.33%-7.64%-43.89%PTIXProtagenic Therapeutics-11.36%+57.10%+49.58%+28.06%-81.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AATNF180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ALIPOLipella Pharmaceuticals0.7204 of 5 stars0.02.00.00.01.13.30.6PTIXProtagenic Therapeutics1.1481 of 5 stars0.05.00.00.02.91.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASPCFAcerus Pharmaceuticals 0.00N/AN/AN/AATNF180 Life Sciences 0.00N/AN/AN/ALIPOLipella Pharmaceuticals 0.00N/AN/AN/APTIXProtagenic Therapeutics 0.00N/AN/AN/ALatest ASPCF, LIPO, ATNF, and PTIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/10/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)4/24/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)4/8/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)3/22/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)3/7/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASPCFAcerus Pharmaceuticals$2.12M0.80N/AN/A($3.38) per share-0.07ATNF180 Life SciencesN/AN/AN/AN/A($0.24) per shareN/ALIPOLipella Pharmaceuticals$536.36K13.78N/AN/A$4.33 per share0.67PTIXProtagenic TherapeuticsN/AN/AN/AN/A$0.83 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASPCFAcerus Pharmaceuticals-$33.82M-$3.57N/A∞N/A-924.33%N/A-74.62%N/AATNF180 Life Sciences-$19.93MN/A0.00∞N/AN/A-558.93%-54.10%8/11/2025 (Estimated)LIPOLipella Pharmaceuticals-$4.62M-$4.08N/A∞N/A-882.82%-192.33%-154.24%N/APTIXProtagenic Therapeutics-$5M-$13.11N/A∞N/AN/A-308.97%-228.73%8/12/2025 (Estimated)Latest ASPCF, LIPO, ATNF, and PTIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ATNF180 Life SciencesN/A-$0.67N/A-$0.67N/AN/A5/14/2025Q1 2025LIPOLipella PharmaceuticalsN/A-$0.64N/A-$0.64N/A$0.13 million5/13/2025Q1 2025PTIXProtagenic TherapeuticsN/A-$2.75N/A-$2.75N/AN/A3/31/2025Q4 2024PTIXProtagenic TherapeuticsN/A-$3.36N/A-$0.24N/AN/A3/27/2025Q4 2024LIPOLipella Pharmaceuticals-$2.43-$1.19+$1.24-$1.19N/A$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASPCFAcerus PharmaceuticalsN/AN/AN/AN/AN/AATNF180 Life SciencesN/AN/AN/AN/AN/ALIPOLipella PharmaceuticalsN/AN/AN/AN/AN/APTIXProtagenic TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASPCFAcerus PharmaceuticalsN/A0.670.34ATNF180 Life SciencesN/A0.190.19LIPOLipella PharmaceuticalsN/A2.972.97PTIXProtagenic TherapeuticsN/A1.801.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASPCFAcerus PharmaceuticalsN/AATNF180 Life Sciences4.07%LIPOLipella Pharmaceuticals74.31%PTIXProtagenic Therapeutics7.97%Insider OwnershipCompanyInsider OwnershipASPCFAcerus PharmaceuticalsN/AATNF180 Life Sciences0.17%LIPOLipella Pharmaceuticals32.11%PTIXProtagenic Therapeutics35.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASPCFAcerus Pharmaceuticals147.71 millionN/ANot OptionableATNF180 Life Sciences75.70 million3.17 millionNo DataLIPOLipella Pharmaceuticals42.55 million821,000Not OptionablePTIXProtagenic Therapeutics2589,0004.71 millionNot OptionableASPCF, LIPO, ATNF, and PTIX HeadlinesRecent News About These CompaniesProtagenic Therapeutics swaps warrants for sharesMay 21 at 6:26 PM | uk.investing.comProtagenic Therapeutics and Phytanix merge in all stock dealMay 21 at 6:26 PM | thepharmaletter.comProtagenic Therapeutics Receives $3.1 Million from Recent Warrant ActivityMay 21 at 9:15 AM | accessnewswire.comSmall Cap Stocks To Follow Now - May 19thMay 21 at 4:09 AM | americanbankingnews.comProtagenic Therapeutics Shares Double After Buyout Offer From Phytanix BioMay 20, 2025 | marketwatch.comProtagenic Therapeutics stock soars on merger to create Neuroactive Biopharmaceutical companyMay 20, 2025 | in.investing.comProtagenic Therapeutics Merges With Phytanix Bio In All-Stock Deal: Retail Turns Extremely BullishMay 20, 2025 | msn.comProtagenic Therapeutics Soars 190% on Merger to Launch Neuroactive Biopharma FirmMay 20, 2025 | msn.comPTIX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Protagenic Therapeutics, Inc. Is Fair to ShareholdersMay 19, 2025 | businesswire.comProtagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic DisordersMay 19, 2025 | accessnewswire.comProtagenic Therapeutics Inc.May 9, 2025 | barrons.comProtagenic Therapeutics, Inc.: Protagenic Therapeutics to Effect 1-for-14 Reverse Stock SplitApril 29, 2025 | finanznachrichten.deProtagenic Therapeutics to Effect 1-for-14 Reverse Stock SplitApril 29, 2025 | accessnewswire.comProtagenic Therapeutics adjusts stock option pricesFebruary 26, 2025 | uk.investing.comPTIX stock touches 52-week low at $0.25 amid sharp annual declineFebruary 11, 2025 | msn.comAvalon Holdings (AMEX:AWX) Stock Quotes, Forecast and News SummaryJanuary 31, 2025 | benzinga.comPerformance Tech stock hits 52-week low at $0.4January 30, 2025 | msn.comProtagenic Therapeutics Inc (PTIX) Stock Settles at $0.53: What’s Contributing to This Price Point?December 24, 2024 | bovnews.comProtagenic Therapeutics faces Nasdaq delisting over equity deficitDecember 5, 2024 | investing.comProtagenic Therapeutics Inc (PTIX) Stock Sees Market Value Hit $3.57 million: What Are the Implications?November 13, 2024 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASPCF, LIPO, ATNF, and PTIX Company DescriptionsAcerus Pharmaceuticals OTCMKTS:ASPCF$0.22 0.00 (0.00%) As of 07/21/2023Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.180 Life Sciences NASDAQ:ATNF$0.94 -0.09 (-8.91%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$0.96 +0.02 (+2.43%) As of 05/23/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Lipella Pharmaceuticals NASDAQ:LIPO$2.90 -0.09 (-3.01%) Closing price 05/23/2025 03:56 PM EasternExtended Trading$2.92 +0.02 (+0.69%) As of 05/23/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.Protagenic Therapeutics NASDAQ:PTIX$4.76 -0.61 (-11.36%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.76 0.00 (-0.11%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
